The interactions of amphiphilic antisense oligonucleotides with serum proteins and their effects on in vitro silencing activity

Biomaterials

Volumn 33, Issue 25, 2012, Pages 5955-5965

  Felber, Arnaud E ^a   Bayó Puxan, Núria ^a,b   Deleavey, Glen F ^b   Castagner, Bastien ^a   Damha, Masad J ^b   Leroux, Jean Christophe ^a  

^a ETH ZURICH   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Albumin; Antisense oligonucleotide; Docosanoic acid; Fatty acid; Nucleic acid; Polymeric micelle

Indexed keywords

ALBUMIN; AMPHIPHILICS; ANTISENSE OLIGONUCLEOTIDES; CELLULAR DELIVERY; DELIVERY METHODS; DELIVERY SYSTEMS; DOCOSAHEXAENOIC ACID; DOSE-DEPENDENT; FREE FATTY ACID; GENE SILENCING; IN-VITRO; POLYION COMPLEX MICELLES; POLYMERIC MICELLE; SERUM PROTEINS; THERAPEUTIC POTENTIALS;

BIOCHEMISTRY; BODY FLUIDS; FATTY ACIDS; GENETIC ENGINEERING; MICELLES; NUCLEIC ACIDS; PROTEINS; SATURATED FATTY ACIDS;

CARRIER CONCENTRATION;

AMPHOPHILE; ANTISENSE OLIGONUCLEOTIDE; BEHENIC ACID; BETA ACTIN; CHOLESTEROL; DOCOSAHEXAENOIC ACID; MESSENGER RNA; PROTEIN BCL 2; SERUM ALBUMIN;

ARTICLE; CODON; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; MICELLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; ZETA POTENTIAL;

BIOLOGICAL ASSAY; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FATTY ACIDS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MALE; MICELLES; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; SERUM ALBUMIN; SURFACE-ACTIVE AGENTS;

EID: 84862211680     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.019     Document Type: Article

References (63)

1. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978, 75:280-284.
2. Stephenson M.L., Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 1978, 75:285-288.
3. Akhtar S., Basu S., Wickstrom E., Juliano R.L. Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res 1991, 19:5551-5559.
4. Lebedeva I., Stein C.A. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001, 41:403-419.
5. Harada A., Togawa H., Kataoka K. Physicochemical properties and nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly(ethylene glycol)-poly(L-lysine) block copolymers. Eur J Pharm Sci 2001, 13:35-42.
6. Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev 2002, 12:103-128.
7. Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999, 1489:69-84.
8. Chan J.H.P., Lim S., Wong W.S.F. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006, 33:533-540.
9. Damha M.J., Wilds C.J., Noronha A., Brukner I., Borkow G., Arion D., et al. Hybrids of RNA and arabinonucleic acids (ANA and 2'F-ANA) are substrates of ribonuclease. H J Am Chem Soc 1998, 120:12976-12977.
10. Kalota A., Karabon L., Swider C.R., Viazovkina E., Elzagheid M., Damha M.J., et al. 2'-Deoxy-2'-fluoro-β-d-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res 2006, 34:451-461.
11. Watts J.K., Katolik A., Viladoms J., Damha M.J. Studies on the hydrolytic stability of 2'-fluoroarabinonucleic acid (2'F-ANA). Org Biomol Chem 2009, 7:1904-1910.
12. Lok C.-N., Viazovkina E., Min K.-L., Nagy E., Wilds C.J., Damha M.J., et al. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-d-arabinose and 2'-deoxyribose nucleotides. Biochemistry 2002, 41:3457-3467.
13. Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010, 50:259-293.
14. Dias N., Stein C.A. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002, 54:263-269.
15. Stein C.A. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol 1996, 14:147-149.
16. Agrawal S., Temsamani J., Tang J.Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 1991, 88:7595-7599.
17. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 1994, 45:932-943.
18. Couto L.B., High K.A. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010, 10:534-542.
19. Zelphati O., Szoka F.C. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996, 13:1367-1372.
20. Lungwitz U., Breunig M., Blunk T., Göpferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005, 60:247-266.
21. Dufresne M.-H., Elsabahy M., Leroux J.-C. Characterization of polyion complex micelles designed to address the challenges of oligonucleotide delivery. Pharm Res 2008, 25:2083-2093.
22. Elsabahy M., Wazen N., Bayó-Puxan N., Deleavey G., Servant M., Damha M.J., et al. Delivery of nucleic acids through the controlled disassembly of multifunctional nanocomplexes. Adv Funct Mater 2009, 19:3862-3867.
23. Kakizawa Y., Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 2002, 54:203-222.
24. Chavany C., Doan T.L., Couvreur P., Puisieux F., Hélèna C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 1992, 9:441-449.
25. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
26. Xu L., Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci 2011, 100:38-52.
27. Ming X., Alam M.R., Fisher M., Yan Y., Chen X., Juliano R.L. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res 2010, 38:6567-6576.
28. Astriab-Fisher A., Sergueev D.S., Fisher M., Ramsay Shaw B., Juliano R.L. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol 2000, 60:83-90.
29. Crooke S.T., Graham M.J., Zuckerman J.E., Brooks D., Conklin B.S., Cummins L.L., et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 1996, 277:923-937.
30. Krieg A.M., Tonkinson J., Matson S., Zhao Q., Saxon M., Zhang L.M., et al. Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A 1993, 90:1048-1052.
31. Raouane M., Desmaële D., Urbinati G., Massaad-Massade L., Couvreur P. Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem 2012, Available from:. http://pubs.acs.org/doi/abs/10.1021/bc200422w, 10.1021/bc200422w.
32. Petrova N.S., Chernikov I.V., Meschaninova M.I., Dovydenko I.S., Venyaminova A.G., Zenkova M.A., et al. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res 2012, 40:2330-2344.
33. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25:1149-1157.
34. Bradley M.O., Swindell C.S., Anthony F.H., Witman P.A., Devanesan P., Webb N.L., et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 2001, 74:233-236.
35. Felber A.E., Castagner B., Elsabahy M., Deleavey G.F., Damha M.J., Leroux J.-C. SiRNA nanocarriers based on methacrylic acid copolymers. J Control Release 2011, 152:159-167.
36. Bayó-Puxan N., Dufresne M.-H., Felber A.E., Castagner B., Leroux J.-C. Preparation of polyion complex micelles from poly(ethylene glycol)-block-polyions. J Control Release 2011, 156:118-127.
37. Wilds C.J., Damha M.J. 2'-Deoxy-2'-fluoro-β-d-arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. Nucleic Acids Res 2000, 28:3625-3635.
38. Bellon L. Oligoribonucleotides with 2'-O-(tert-butyldimethylsilyl) groups. Curr protoc nucleic acid chem 2000, 3.6.1-3.6.13. John Wiley & Sons, Inc., New York. S.L. Beaucage, D.E. Bergstrom, G.D. Glick, R.A. Jones (Eds.).
39. Winkler J., Stessl M., Amartey J., Noe C.R. Off-target effects related to the phosphorothioate modification of nucleic acids. ChemMedChem 2010, 5:1344-1352.
40. Anderson E.M., Miller P., Ilsley D., Marshall W., Khvorova A., Stein C.A., et al. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther 2006, 13:406-414.
41. Damha M.J., Ogilvie K.K. Oligoribonucleotide synthesis: the silyl-phosphoramidite method. Protocols for oligonucleotides and analogs 1993, 81-114. The Humana Press Inc., Totowa. S. Agrawal (Ed.).
42. Min K.-L., Viazovkina E., Galarneau A., Parniak M.A., Damha M.J. Oligonucleotides comprised of alternating 2'-deoxy-2'-fluoro-β-d-arabinonucleosides and d-2'-deoxyribonucleosides (2'F-ANA/DNA 'altimers') induce efficient RNA cleavage mediated by RNase H. Bioorg Med Chem Lett 2002, 12:2651-2654.
43. Simard J.R., Zunszain P.A., Ha C.-E., Yang J.S., Bhagavan N.V., Petitpas I., et al. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci U S A 2005, 102:17958-17963.
44. Bhattacharya A.A., Grüne T., Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000, 303:721-732.
45. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
46. MacKellar C., Graham D., Will D.W., Burgess S., Brown T. Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucleic Acids Res 1992, 20:3411-3417.
47. o/w) of fatty acids using multiple linear regression (MLR). OUAC 2011, 22:79-86.
48. Chiosa V., Mandravel C., Teodoreanu C.-L., Stanculescu I. Comparison of QSPR properties for cholesterol and cholestanol oligomeric association forms. Rev Roum Chim 2006, 51:135-140.
49. Wang Y., Li L., Jiang W., Yang Z., Zhang Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett 2006, 16:2974-2977.
50. Shaikh I.A.A., Brown I., Schofield A.C., Wahle K.W.J., Heys S.D. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-κB pathway. Prostate 2008, 68:1635-1646.
51. Jones R., Hawkins R., Eatock M., Ferry D., Eskens F., Wilke H., et al. A phase II open-label study of DHA-paclitaxel (taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 2007, 61:435-441.
52. Payne M., Ellis P., Dunlop D., Ranson M., Danson S., Schacter L., et al. DHA-paclitaxel (taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol 2006, 1:984-990.
53. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
54. Lau S., Graham B., Cao N., Boyd B.J., Pouton C.W., White P.J. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. Mol Pharm 2012, 9:71-80.
55. Stremmel W., Pohl J., Ring A., Herrmann T. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 2001, 36:981-989.
56. Schwenk R.W., Holloway G.P., Luiken J.J.F.P., Bonen A., Glatz J.F.C. Fatty acid transport across the cell membrane: regulation by fatty acid transporters. Prostaglandins Leukot Essent Fatty Acids 2010, 82:149-154.
57. Tesseromatis C., Alevizou A. The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metab Pharmacokinet 2008, 33:225-230.
58. Sansom L.N., Evans A.M. What is the true clinical significance of plasma protein binding displacement interactions?. Drug Saf 1995, 12:227-233.
59. Vorum H., Honoré B. Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J Pharm Pharmacol 1996, 48:870-875.
60. Brodersen R., Andersen S., Vorum H., Nielsen S.U., Pedersen A.O. Multiple fatty acid binding to albumin in human blood plasma. Eur J Biochem 1990, 189:343-349.
61. 13C nuclear magnetic resonance study. J Clin Invest 1991, 87:1431-1441.
62. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 2011, 44:1105-1113.
63. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581-593.